---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-042331"
form_type: "8-K"
ticker: "IVVD"
cik: "0001832038"
company_name: "Invivyd, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:44:52.316402+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Invivyd Q4 2024 PEMGARDA revenue $13.8M (+48% QoQ); FY2024 net loss $169.9M; FDA rejects EUA expansion for treatment

## Summary
- Q4 2024 net product revenue $13.8M, up 48% from Q3 $9.3M; full-year 2024 net product revenue $25.4M.
- Cash and cash equivalents $69.3M at Dec 31, 2024; targeting near-term profitability by end of 1H 2025 with existing cash and expected revenue growth.
- FDA declined request to expand PEMGARDA EUA for treatment of mild-to-moderate COVID-19 in immunocompromised; Invivyd submitted reconsideration request.
- Phase 1 data for VYD2311 shows average 17-fold greater neutralization potency than pemivibart; commercial mfg substantially completed.
- Net loss for 2024 $169.9M ($1.43 per share) vs $198.6M ($1.81 per share) in 2023.

## SEC filing metadata
- accession: 0000950170-25-042331
- form_type: 8-K
- ticker: IVVD
- cik: 0001832038
- company_name: Invivyd, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1832038/000095017025042331/0000950170-25-042331-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1832038/000095017025042331/ivvd-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-042331
- JSON: https://secwatch.observer/filing/0000950170-25-042331.json
- Plain text: https://secwatch.observer/filing/0000950170-25-042331.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.